1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. France >
  5. Aviragen Therapeutics Acquires Anaconda Pharma SAS

M&A Deal Summary

Aviragen Therapeutics Acquires Anaconda Pharma SAS

On June 3, 2015, Aviragen Therapeutics acquired life science company Anaconda Pharma SAS

Acquisition Highlights
  • This is Aviragen Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Aviragen Therapeutics’ 1st transaction in France.

M&A Deal Summary
Date 2015-06-03
Target Anaconda Pharma SAS
Sector Life Science
Buyer(s) Aviragen Therapeutics
Deal Type Add-on Acquisition
Advisor(s) Stifel (Financial)
Dechert (Legal)

Target

Anaconda Pharma SAS

Paris, France
Anaconda Pharma SAS is a biotechnology company.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Aviragen Therapeutics

Alpharetta, Georgia, United States
Category Company
Sector Life Science
Employees19
DESCRIPTION

Aviragen Therapeutics, Inc. is a developer of innovative products for the prevention and treatment of serious and potentially life-threatening infectious diseases.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: France M&A 1 of 1
Year: 2015 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-10-30 Nabi Biopharmaceuticals

Rockville, Maryland, United States

Nabi Biopharmaceuticals (NABI) has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.

Buy $100M
Mergr

Solution for

Product

Company

Legal